Value and Access Principles

Our Focus

Servier takes an aggressive approach to innovation, focusing on unmet needs in cancer care, and investing in areas where others have failed or considered it too risky.

We are guided by a passion for innovation and improving the lives of people with difficult and rare cancers, and the lives of their families and caregivers.

Our ability to sustain high levels of re-investment from our brand medicine revenue back into our R&D focus areas, owed to our unique governance structure, allows us to price our medicines in ways that are targeted to fueling future innovation.

Learn more about Servier’s approach to value-based pricing our medicines to ensure equitable access to innovative treatment options for patients living with cancer.

To learn more about Servier’s value-based approach for offering a targeted treatment option for patients with IDH-mutated glioma specifically, click below.

Vorasidenib Value Proposition

Accessing Servier Medicines

Servier performs a comprehensive assessment of value in our approach to pricing medicines, which considers the ability for our treatments to re-define care options in cancer types with high unmet need, as well as their social and economic value. As part of this pricing approach, we are committed to ensuring our patients in the U.S. have access to our treatments, regardless of their financial or social circumstances. Supporting patients is our ONE priority. To achieve this, we offer a suite of resources to best serve our patients:

ServierONE, our all-in-one personal support program for patient financial assistance. ServierONE can assist with determining insurance coverage, one-on-one support through care managers and access to educational tools.
Our Patient Office addresses patient journey challenges from the moment of diagnosis until long after their treatment ends.
Our Patient Expert Council contains cancer patients and their caregivers and provides insights back to us on meeting true patient needs.
Expanded Access is for patients who may be eligible to participate in Servier’s clinical trials to access investigational drugs before the drugs have been approved for a current commercial use in the patient’s disease.